These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 12022250)
1. Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: a case report. Giner V; Fernández C; Esteban MJ; Galindo MJ; Forner MJ; Guix J; Redón J Am J Hypertens; 2002 May; 15(5):465-7. PubMed ID: 12022250 [TBL] [Abstract][Full Text] [Related]
2. Papillary necrosis associated with the HIV protease inhibitor indinavir. Dieleman JP; van der Feltz M; Bangma CH; Stricker BH; van der Ende ME Infection; 2001 Aug; 29(4):232-3. PubMed ID: 11545487 [TBL] [Abstract][Full Text] [Related]
3. Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease. Calista D; Morri M Eur J Dermatol; 2008; 18(1):84-5. PubMed ID: 18086600 [No Abstract] [Full Text] [Related]
4. [Antiretroviral therapy with nelfinavir for patient infected, by HIV and secondary diabetes mellitus due to indinavir]. Pedrol Clotet E; Rodellar Oncins MT; Soler Sendra A; Martínez Losada EJ Med Clin (Barc); 2002 Sep; 119(10):398-9. PubMed ID: 12372178 [No Abstract] [Full Text] [Related]
5. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. Henry K; Kitch D; Dube M; Zackin R; Parker RA; Sprecher D; Hammer S; Currier J; AIDS; 2004 Dec; 18(18):2434-7. PubMed ID: 15622323 [No Abstract] [Full Text] [Related]
6. Reversible posterior leukoencephalopathy syndrome in a patient with hypertensive encephalopathy--case report. Yoshida K; Yamamoto T; Mori K; Maeda M Neurol Med Chir (Tokyo); 2001 Jul; 41(7):364-9. PubMed ID: 11488003 [TBL] [Abstract][Full Text] [Related]
7. Epidural lipomatosis secondary to indinavir in an HIV-positive patient. Cersósimo MG; Lasala B; Folgar S; Micheli F Clin Neuropharmacol; 2002; 25(1):51-4. PubMed ID: 11852297 [TBL] [Abstract][Full Text] [Related]
8. Indinavir use: associated reversible hair loss and mood disturbance. Harry TC; Matthews M; Salvary I Int J STD AIDS; 2000 Jul; 11(7):474-6. PubMed ID: 10919491 [TBL] [Abstract][Full Text] [Related]
9. Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment. Fraaij PL; Verweel G; van Rossum AM; Hartwig NG; Burger DM; de Groot R Infection; 2007 Jun; 35(3):186-9. PubMed ID: 17565462 [TBL] [Abstract][Full Text] [Related]
10. Relapsing blepharitis in patients under highly active antiretroviral therapy including indinavir. Lozano F; León EM; Mira JA; Corzo JE; Gómez-Mateos JM AIDS; 2004 Jan; 18(2):354-6. PubMed ID: 15075566 [No Abstract] [Full Text] [Related]
11. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L; Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753 [TBL] [Abstract][Full Text] [Related]
12. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079 [TBL] [Abstract][Full Text] [Related]
14. Adhesive capsulitis of the shoulder in human immunodeficiency virus-positive patients during highly active antiretroviral therapy. De Ponti A; Viganò MG; Taverna E; Sansone V J Shoulder Elbow Surg; 2006; 15(2):188-90. PubMed ID: 16517362 [TBL] [Abstract][Full Text] [Related]
15. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity. Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876 [TBL] [Abstract][Full Text] [Related]
16. [Paronychia in patients infected with HIV treated with indinavir]. García García MJ; Morano Amado LE; Allegue Rodríguez F; Miralles Alvarez C; Ocampo Hermida A Rev Clin Esp; 2001 Aug; 201(8):455-8. PubMed ID: 11599157 [TBL] [Abstract][Full Text] [Related]
17. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Tam CS; Galanos J; Seymour JF; Pitman AG; Stark RJ; Prince HM Am J Hematol; 2004 Sep; 77(1):72-6. PubMed ID: 15307110 [TBL] [Abstract][Full Text] [Related]
18. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183 [TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity of antiretroviral therapy in an HIV-infected patient. Said SM; Nasr SH; Samsa R; Markowitz GS; D'Agati VD Kidney Int; 2007 May; 71(10):1071-5. PubMed ID: 17311070 [No Abstract] [Full Text] [Related]
20. Rheumatological complications associated with the use of indinavir and other protease inhibitors. Florence E; Schrooten W; Verdonck K; Dreezen C; Colebunders R Ann Rheum Dis; 2002 Jan; 61(1):82-4. PubMed ID: 11779768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]